The stock of Esperion Therapeutics Inc (NASDAQ:ESPR) is a huge mover today! About 266,294 shares traded hands. Esperion Therapeutics Inc (NASDAQ:ESPR) has declined 40.31% since April 14, 2016 and is downtrending. It has underperformed by 45.00% the S&P500.
The move comes after 9 months positive chart setup for the $248.31M company. It was reported on Nov, 16 by Barchart.com. We have $32.26 PT which if reached, will make NASDAQ:ESPR worth $446.96M more.
Esperion Therapeutics Inc (NASDAQ:ESPR) Ratings Coverage
Out of 13 analysts covering Esperion Therapeutics (NASDAQ:ESPR), 6 rate it a “Buy”, 1 “Sell”, while 6 “Hold”. This means 46% are positive. Esperion Therapeutics has been the topic of 31 analyst reports since July 28, 2015 according to StockzIntelligence Inc. The stock has “Overweight” rating given by Barclays Capital on Wednesday, February 24. The stock has “Sell” rating given by Chardan Capital Markets on Tuesday, September 29. The stock of Esperion Therapeutics Inc (NASDAQ:ESPR) earned “Neutral” rating by JP Morgan on Wednesday, June 29. The firm earned “Outperform” rating on Tuesday, December 15 by RBC Capital Markets. Citigroup maintained it with “Buy” rating and $22 target price in Wednesday, June 29 report. The rating was maintained by Chardan Capital Markets with “Sell” on Monday, July 27. The firm has “Neutral” rating by Chardan Capital Markets given on Friday, February 26. The firm earned “Buy” rating on Monday, October 26 by Lake Street. The stock of Esperion Therapeutics Inc (NASDAQ:ESPR) earned “Sector Perform” rating by RBC Capital Markets on Wednesday, June 29. The stock of Esperion Therapeutics Inc (NASDAQ:ESPR) has “Buy” rating given on Monday, August 10 by Needham.
According to Zacks Investment Research, “Esperion Therapeutics, Inc. is a biopharmaceutical company. It focused on the research, development and commercialization of therapies for low-density lipoprotein cholesterol and other cardiometabolic risk factors. Esperion Therapeutics, Inc. is based in Plymouth, Michigan.”
Insitutional Activity: The institutional sentiment increased to 1.27 in 2016 Q2. Its up 0.11, from 1.16 in 2016Q1. The ratio increased, as 13 funds sold all Esperion Therapeutics Inc shares owned while 24 reduced positions. 9 funds bought stakes while 38 increased positions. They now own 14.43 million shares or 7.41% less from 15.58 million shares in 2016Q1.
Quantitative Invest Lc accumulated 0.01% or 11,300 shares. Dimensional Fund Advsrs L P has 25,963 shares for 0% of their US portfolio. Glacier Peak Cap Limited Liability Corp holds 38,048 shares or 0.4% of its portfolio. Equitec Proprietary Limited Liability Corporation reported 300 shares or 0% of all its holdings. Cam Gru Hldgs A S has invested 0% of its portfolio in Esperion Therapeutics Inc (NASDAQ:ESPR). State Street owns 246,271 shares or 0% of their US portfolio. Jpmorgan Chase And last reported 142,161 shares in the company. Royal Bank Of Canada reported 5,790 shares or 0% of all its holdings. Metropolitan Life Communication holds 9,258 shares or 0% of its portfolio. Pnc Finance Ser Grp owns 71 shares or 0% of their US portfolio. Bnp Paribas Arbitrage Sa reported 565 shares or 0% of all its holdings. Morgan Stanley accumulated 0% or 126,530 shares. Savings Bank Of Montreal Can accumulated 0% or 21,735 shares. Blackrock Inc holds 3,401 shares or 0% of its portfolio. Susquehanna Int Gru Ltd Liability Partnership reported 56,644 shares or 0% of all its holdings.
More notable recent Esperion Therapeutics Inc (NASDAQ:ESPR) news were published by: Marketwatch.com which released: “Esperion Therapeutics downgraded to neutral from buy at Citigroup” on November 22, 2013, also Fool.com with their article: “Esperion Therapeutics Inc Sinks After FDA Says, “Ask Us in 2019″” published on June 29, 2016, Fool.com published: “Why Esperion Therapeutics, Inc. Stock Cratered Today” on September 29, 2015. More interesting news about Esperion Therapeutics Inc (NASDAQ:ESPR) were released by: Prnewswire.com and their article: “Shareholder Class Action Filed Against Esperion Therapeutics, Inc. – ESPR” published on January 14, 2016 as well as Fool.com‘s news article titled: “Why Esperion Therapeutics, Inc. Shares Burst Today.” with publication date: March 25, 2015.
ESPR Company Profile
Esperion Therapeutics, Inc., incorporated on January 22, 2008, is a pharmaceutical company. The Firm is focused on developing and commercializing oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of patients with elevated LDL-C. The Company’s segment is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C. The Company’s lead product candidate is ETC-1002, or bempedoic acid. The Firm is engaged in conducting a global Phase III long-term safety and tolerability study of bempedoic acid in patients with hyperlipidemia whose LDL-C is not adequately controlled with low- and moderate-dose statins.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.